Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
0–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
All patients receiving Tabrecta for MET exon 14 skipping mutation-positive unresectable advanced/recurrent NSCLC during a specified post-marketing period
You may not be if
\-
Clareo Health | Special Drug Use-results Surveillance of Tabrecta Tablets
